You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firms will conduct PacBio whole-genome sequencing on epilepsy patients to generate variant profiles that can help the development of diagnostic assays.
The company's adaptive low-resource testing technology requires no instrumentation and limited equipment, making it adaptable to settings without clinical lab infrastructure.
Blueprint provides 3,900 targeted single-gene and more than 200 panel tests covering 14 medical specialties, leveraging NGS and bioinformatics methods.
Evogen launched a clinical trial to further validate its proteomic test for distinguishing between epileptic seizures and psychogenic non-epileptic seizures.
Apatagen is developing the aptamer-based test to diagnose human carriers of pork tapeworm and prevent neurocysticercosis, which causes adult-onset epilepsy.
Acquired epilepsy is a form of the neurological disorder that results from other conditions such as stroke, infections, and traumatic brain injury.
The company announced this week the expansion of a genetic testing program for US patients with inherited retinal disease that it has run with partners since 2017.
Evogen's protein biomarker-based test is designed to stratify actively seizing patients from those who have not experienced a recent seizure.
Free genetic testing on a broad gene panel is available to children, from birth to five years old, if they've had an unprovoked seizure.
The effort could lead to Metafora's flow cytometry-based assay becoming the standard of care for diagnosing the disease in France.